Jazz Pharmaceuticals shared a post on LinkedIn:
“At STAT Breakthrough Summit East last week, Josh Allen, Chief Scientific Officer, Oncology, spoke with STAT about how we are driving innovative research in rare diseases to advance therapies that redefine standards of care for patients and their families. Listen here.”
Other articles from Jazz Pharmaceuticals.